ObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSV – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

ObsEva Price Performance

Shares of OBSV opened at $0.12 on Friday. The firm has a market cap of $9.66 million, a PE ratio of -0.13 and a beta of 0.68. The company’s fifty day moving average is $0.18 and its two-hundred day moving average is $0.17. ObsEva has a fifty-two week low of $0.08 and a fifty-two week high of $2.14.

Institutional Investors Weigh In On ObsEva

A number of institutional investors have recently modified their holdings of OBSV. Credit Suisse AG lifted its stake in shares of ObsEva by 11.0% in the 4th quarter. Credit Suisse AG now owns 1,750,573 shares of the company’s stock worth $255,000 after acquiring an additional 173,455 shares during the period. Bank of America Corp DE increased its stake in ObsEva by 54,142.2% in the 1st quarter. Bank of America Corp DE now owns 484,383 shares of the company’s stock valued at $731,000 after buying an additional 483,490 shares during the period. Pictet Asset Management SA increased its stake in ObsEva by 25.8% in the 3rd quarter. Pictet Asset Management SA now owns 371,595 shares of the company’s stock valued at $53,000 after buying an additional 76,196 shares during the period. Two Sigma Investments LP bought a new stake in ObsEva in the third quarter worth approximately $25,000. Finally, Millennium Management LLC bought a new stake in ObsEva in the second quarter worth approximately $192,000. Institutional investors own 17.52% of the company’s stock.

About ObsEva

(Get Rating)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.